What Better Gout Trials Might Look Like
Executive Summary
FDA comments in Ironwood's Zurampic review suggest what the agency would like to see from gout clinical programs.
You may also be interested in...
Drug Review Profiles: Behind The Scenes At US FDA
A year in our long-running series of deep dives into FDA review documents.
US FDA's Search For Meaning: Interpretation Of Regulatory Language Can Inspire Conflict In Drug Reviews
The Pink Sheet's Drug Review Profile series illustrates the challenge of reconciling review realities and broad statutory directives.
With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout
Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.